52 completed, 4 terminated, 4 unknown, 2 active not recruiting. 29 Phase 1, 26 Phase 2, 10 Phase 3, 8 Phase 4, 2 Not applicable.
Follow Carbidopa: new trials by email Literature Review of Carbidopa trials Research Report on Carbidopa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brain Dopamine Biomarker Levadopa/Carbidopa eyedrops, Sham, Levodopa/Carbidopa (Sinemet) - Parkinson Disease, Healthy Adult Participants | Not yet recruiting | University of South Florida | 50 | 2026-10-01 | 2026-08-12 | |
| A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg) - Healhty | Phase 1 | Completed | Shanghai WD Pharmaceutical Co., Ltd. | 12 | 2026-03-17 | 2026-09-23 |
| Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease LECIG (levodopa, carbidopa, entacapone intestinal gel), Best oral medication - PARKINSON DISEASE (Disorder) | Phase 3 | Recruiting | University Hospital Tuebingen | 150 | 2025-10-27 | 2026-07-13 |
| Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg - Parkinsonian Signs in Older Persons | Phase 1 / Phase 2 | Completed | University of Michigan | 5 | 2024-10-29 | 2026-04-14 |
| Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg, Placebo 1 - Parkinsonian Signs in Older Persons | Phase 1 / Phase 2 | Completed | University of Michigan | 13 | 2024-03-15 | 2025-06-17 |
| Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in the Postprandial State in Healthy Chinese Subjects Test (T) Entacapone,Levodopa and Carbidopa Tablets (II), Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II) - Healthy | Phase 1 | Unknown | The Affiliated Hospital of Qingdao University | 36 | 2023-12-20 | 2023-12-22 |
| A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects Carbidopa capsule, Moxifloxacin Tablets, USP, Placebo - Cardiac Repolarization in Healthy Subjects | Phase 1 | Completed | Impax Laboratories, LLC | 35 | 2023-10-30 | 2024-03-05 |
| Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in Healthy Chinese Subjects Test (T) Entacapone,Levodopa and Carbidopa Tablets (II), Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II) - Healthy | Phase 1 | Unknown | The Affiliated Hospital of Qingdao University | 68 | 2023-08-17 | 2023-08-04 |
| Bioavailability of Levodopa 250 mg and Carbidopa 25 mg With Regards to Reference Product Levodopa 250mg and Carbidopa 25mg Test Drug tablet, Levodopa 250mg and Carbidopa 25mg Referent Product tablet - Bioequivalence | Phase 1 | Completed | Laboratorios Andromaco S.A. | 44 | 2022-02-14 | 2022-03-08 |
| Histaminergic Basis of Fatigue in Multiple Sclerosis L-Histidine, Placebo, Lodosyn - Multiple Sclerosis | Phase 2 | Withdrawn | University of Miami | 2022-01-01 | 2021-07-29 | |
| Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease Stalevo, Carbidopa and Levodopa Controlled Release Tablets - Parkinson Disease | Phase 4 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 180 | 2022-01-01 | 2023-02-16 |
| Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients continuous oral delivery of levodopa/carbidopa - Parkinson's Disease | Phase 2 | Completed | SynAgile Corporation | 17 | 2021-06-16 | 2022-08-10 |
| Dopaminergic Dysfunction in Late-Life Depression L-Dopa, Placebo - Late Life Depression, Cognitive Decline | Phase 2 | Completed | Vanderbilt University Medical Center | 79 | 2021-02-15 | 2026-08-06 |
| Neurobiological Drivers of Mobility Resilience: The Dopaminergic System carbidopa - Parkinsonian Signs in Older Persons | Phase 1 / Phase 2 | Completed | University of Michigan | 14 | 2021-02-08 | 2024-04-04 |
| Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD) - Parkinson's Disease (PD) | Phase 3 | Completed | AbbVie | 174 | 2020-10-19 | 2022-11-18 |
| Effects of 5HTP on the Injured Human Spinal Cord 5-Hydroxytryptophan 100 MG, 5-Hydroxytryptophan, Carbidopa - Spinal Cord Injuries | Phase 2 / Phase 3 | Active not recruiting | University of Alberta | 6 | 2020-07-01 | 2026-09-16 |
| Vigor and the LDR in Parkinson Disease carbidopa/levodopa, as prescribed by treating physician - Parkinson Disease | Phase 4 | Completed | University of Michigan | 19 | 2020-02-12 | 2025-07-18 |
| [18F]F-DOPA Imaging in Patients With Autonomic Failure [18F]FDOPA, Carbidopa 200mg oral dose, Entacapone 400mg oral dose - Autonomic Failure, Pure Autonomic Failure | Phase 1 | Recruiting | Daniel Claassen | 40 | 2020-02-04 | 2026-03-16 |
| Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity carbidopa/levodopa and celecoxib, placebo1 and celecoxib, placebo1 and placebo2 - Chronic Back Pain | Phase 2 | Withdrawn | Second Affiliated Hospital of Wenzhou Medical University | 2019-10-01 | 2020-01-09 | |
| Effects of 5HTP and LDOPA on CNS Excitability After SCI 5HTP, L-DOPA, Placebo oral tablet - Spinal Cord Injuries | Phase 2 / Phase 3 | Suspended | Jessica M D'Amico | 30 | 2019-06-19 | 2022-10-17 |
Showing 20 of 68. Sign in to see all of them.
Parkinson Disease (34) · Multiple System Atrophy (3) · Pure Autonomic Failure (3) · Cocaine-Related Disorders (2) · Depressive Disorder, Major (2) · Disruptive, Impulse Control, and Conduct Disorders (2) · Dysautonomia, Familial (2) · Fatigue (2) · Hypertension (2) · Multiple Sclerosis (2) · Pain (2) · Spinal Cord Injuries (2) · Angelman Syndrome (1) · Asthma (1) · Autonomic Nervous System Diseases (1)
Orion Corporation, Orion Pharma (9) · University of Michigan (4) · Acorda Therapeutics (3) · Bial - Portela C S.A. (3) · Vanderbilt University (3) · AbbVie (2) · AbbVie (prior sponsor, Abbott) (2) · NYU Langone Health (2) · NeuroDerm Ltd. (2) · New York State Psychiatric Institute (2) · The Affiliated Hospital of Qingdao University (2) · University of Miami (2) · Vanderbilt University Medical Center (2) · XenoPort, Inc. (2) · Boston Children's Hospital (1)
United States (30) · Finland (8) · Canada (4) · China (4) · Australia (3) · Italy (3) · Spain (3) · Germany (2) · Israel (2) · Portugal (2) · United Kingdom (2) · Greece (1) · Hungary (1) · India (1) · Luxembourg (1)
Chatkaew Pongmala, PhD (2) · Harald Murck, MD, PhD (2) · Italo Biaggioni, MD (2) · Jessica D'Amico, PhD (2) · Kottil Rammohan, MD (2) · Mika Scheinin, MD (2) · Yu Cao (2) · Adam Bisaga, M.D. (1) · Alfredo J Gamboa, MD (1) · BinBin Wu, doctor (1) · Bret Rutherford, MD (1) · Claudia Trenkwalder, MD (1)
PMID 11927799, PMID 12119802, PMID 15738343, PMID 10662747, PMID 10851208, PMID 11904109, PMID 12832331, PMID 12923400, PMID 15066944, PMID 15710782, PMID 16391172, PMID 16533484, PMID 17515447, PMID 17515448, PMID 18426998, PMID 19047577, PMID 19738158, PMID 20837887, PMID 22311903, PMID 22801444, PMID 23266540, PMID 26725544, PMID 27271310, PMID 28027332, PMID 30361296, PMID 30824559, PMID 34236101, PMID 36402160, PMID 38345741, PMID 38698639, PMID 39727053, PMID 40979212, PMID 40982270, PMID 41045349, PMID 41324738, PMID 41701756, PMID 42525438, PMID 9369256, PMID 9727818, PMID 9890307
U01AG061393 (3), 2018 (2), 2005 (1), 2016 (1), 2019 (1), 2025 (1), P50DA009236 (1), P50DA009262 (1), R21NS114749 (1), R33MH110029 (1)